Contact
searchSearch
HMP Global
Industry Posters

Reduction of Masseter Muscle Prominence After Treatment with OnabotulinumtoxinA: Results from a Phase 3 Double-Blind, Randomized, Placebo-Controlled Study Period in the United States

Music City SCALE 2026

Terrence Keaney, Heather Woolery-Lloyd, Jennifer Nash, Michael Gold, Deanne Mraz, René Hopfinger, Reva McCaskill, Grace Pan, Catherine Foley, Xinyi Wang

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Popular Articles

psoriatic arthritis
News
Efficacy and Safety of Pharmacologic Treatment of Psoriatic Arthritis
07/12/2024
Jessica Garlewicz
Researchers conducted a systematic literature review, examining conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs.
Researchers conducted a systematic literature review, examining conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs.
Researchers conducted a...
07/12/2024
The Dermatologist
Clinical Insights
Treating Acne Sequelae
09/06/2024
Riya Gandhi, MA
There are many new devices available to target the aftereffects of acne, allowing dermatologists to tailor treatment plans for the best possible patient outcomes.
There are many new devices available to target the aftereffects of acne, allowing dermatologists to tailor treatment plans for the best possible patient outcomes.
There are many new devices...
09/06/2024
The Dermatologist
Illustration of a T cell
QUIZ
Test Your Knowledge: The Immunology of Alopecia Areata
11/04/2024
11/04/2024
The Dermatologist
Chief Medical Editor Message
Communication in Shared Decision-Making
08/06/2024
Steven R. Feldman, MD, PhD
As science-based professionals, I think our tendency is to provide the best numeric statistics available to our patients.
As science-based professionals, I think our tendency is to provide the best numeric statistics available to our patients.
As science-based professionals,...
08/06/2024
The Dermatologist
PsA
FDA Alerts
Bimekizumab FDA Approved for the Treatment of Psoriatic Arthritis
09/24/2024
Riya Gandhi, MA
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug...
09/24/2024
The Dermatologist
June 2026 issue

Current Issue

June 2026
Volume 34
Issue 4
Current Issue
Issue Archive

Latest Quizzes and Trivia

Quiz
Type 2 Endotypes and Therapeutic Strategy in Prurigo Nodularis
06/25/2026
Riya Gandhi, MA
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type...
06/25/2026
The Dermatologist
itch
Quiz
Fibrosis and Persistent Itch in Prurigo Nodularis
06/15/2026
Riya Gandhi, MA
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding...
06/15/2026
The Dermatologist
brain
Quiz
Neuroimmune Mechanisms and Cytokine Signaling in Prurigo Nodularis
06/05/2026
Riya Gandhi, MA
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in...
06/05/2026
The Dermatologist
Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use